|2.||Alzheimer Disease (Alzheimer's Disease)
|1.||Bahn, Yong-Sun: 7 articles (01/2015 - 01/2011)|
|2.||Hope, William W: 7 articles (01/2014 - 01/2008)|
|3.||Jung, Kwang-Woo: 6 articles (01/2015 - 01/2011)|
|4.||Lortholary, Olivier: 6 articles (11/2013 - 02/2007)|
|5.||Harrison, Thomas S: 5 articles (01/2014 - 02/2010)|
|6.||Kepa, Lucjan: 5 articles (01/2012 - 01/2005)|
|7.||Dorta-Contreras, Alberto J: 5 articles (01/2011 - 01/2008)|
|8.||Noris-García, E: 5 articles (10/2008 - 03/2000)|
|9.||Dorta-Contreras, A J: 5 articles (10/2008 - 03/2000)|
|10.||Lai, Shih-Chan: 4 articles (12/2014 - 09/2006)|
|1.||Amphotericin B (Amphotericin)FDA LinkGeneric
07/01/2000 - "The central nervous system (CNS) distribution and antifungal efficacy of all 4 approved formulations of amphotericin B (AmB) were investigated in a rabbit model of hematogenous Candida albicans meningoencephalitis. "
01/01/2011 - "We also reviewed previously reported 8 Indian cases of primary amoebic meningoencephalitis (PAM) and observed that for the last 5 years, none of the patients responded to amphotericin B. "
01/01/2008 - "Combination of amphotericin B+flucytosine (AMB+5FC) was the best regimen for induction therapy in patients with meningoencephalitis and in all patients with high fungal burden and abnormal neurology. "
04/01/1999 - "Despite the initiation of specific treatment with amphotericin B, the patient died on day 12 following surgery for cryptococcal meningoencephalitis."
07/05/1986 - "Amphotericin B doses for primary amoebic meningoencephalitis."
|2.||Amyloid (Amyloid Fibrils)IBA
01/01/2008 - "However, initial human trials of active amyloid-beta (Abeta) vaccination were halted early because of a serious safety issue: meningoencephalitis in 6% of subjects. "
12/01/2007 - "Immunotherapy is a leading approach for amyloid clearance, despite the early termination of the Elan clinical trial with active immunization due to a few cases of meningoencephalitis. "
04/01/2013 - "On the contrary, side effects emerged, such as meningoencephalitis, vasogenic edema, which are currently called amyloid related imaging abnormalities (ARIA)-E and microhemorrhage (ARIA-H). "
01/01/2004 - "Neuropathological examination in that patient showed meningoencephalitis, and focal atypically low numbers of diffuse and neuritic plaques but not of vascular amyloid, nor regression of tau pathology in neurofibrillary tangles and neuropil threads. "
05/01/2006 - "Although immunotherapy holds great promise for the treatment of Alzheimer's disease, clinical trials of active amyloid-beta vaccination of patients with Alzheimer's disease were discontinued after some patients developed meningoencephalitis. "
|3.||Fluconazole (Zonal)FDA LinkGeneric
06/01/2013 - "Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints."
03/01/1998 - "This report documents the diagnosis of a case of cryptococcal meningoencephalitis and its management with the new antifungal agent, fluconazole."
08/01/2002 - "In conclusion, high dose fluconazole administered post-infection, or as prophylaxis, may be highly efficacious in the treatment and prevention of meningoencephalitis."
01/15/2009 - "[Cryptococcal meningoencephalitis related to HIV infection with resistance to fluconazole, relapse, and IRIS]."
01/01/1991 - "Cryptococcal meningoencephalitis in a patient with Hodgkin's lymphoma: successful treatment with fluconazole."
09/01/2012 - "AN-1792 showed promising results with regards to Aβ clearance and cognitive function improvement, but also exhibited an increased risk of Th1 mediated meningoencephalitis. "
01/01/2015 - "In the phase IIa AN1792 trial, 6% of patients who received the vaccination were diagnosed with meningoencephalitis as an adverse effect. "
01/01/2015 - "Clinical Aβ vaccination trial AN1792 was interrupted due to the development in 6 % of the patients of meningoencephalitis likely involving pro-inflammatory CD4(+) T cells. "
11/01/2005 - "The second trial of vaccine, AN1792, for Alzheimer's patients was halted because of meningoencephalitis found in 6% of patients and one autopsy case was reported. "
02/01/2005 - "The cause of the meningoencephalitis in the patients that received the vaccine has not been definitively determined; however, analysis of two case reports from the AN-1792 vaccine trial suggest that the meningoencephalitis may have been caused by a T cell-mediated autoimmune response, whereas production of anti-Abeta Abs may have been therapeutic to the AD patients. "
04/01/1982 - "[Diagnostic efficacy of the determination of antibodies against herpes simplex virus type I in the cerebrospinal fluid and blood of children with meningoencephalitis]."
07/01/2008 - "In this study we aimed to evaluate the use of polymerase chain reaction (PCR) and detection of intrathecally synthesized antibodies by serological methods in viral meningoencephalitis suspected cases to determine HSV as the causative agent. "
01/01/2007 - "However, because of meningoencephalitis in clinical trials of active vaccination, approaches using therapeutic antibodies may be preferred. "
06/01/1988 - "The studies suggest that antibodies play an important role in the ACF-induced resistance to experimental naegleria meningoencephalitis."
11/01/2015 - "However, immunization with synthetic human Aβ1-42 has resulted in meningoencephalitis in 6% of patients and generated only low-titer anti-Aβ42 antibodies. "
|6.||QS 21 (QS21)IBA
01/01/2009 - "However, a Phase II clinical trial of active immunization using full-length human Abeta1-42 peptide and a strong Th1-biased adjuvant, QS-21, ended prematurely in 2002 because of the onset of meningoencephalitis in approximately 6% of the AD patients enrolled in the study. "
03/20/2006 - "Immunization with Abeta42 formulated in the Th1-type adjuvant QS21 was beneficial for AD patients with significant titers of anti-Abeta antibodies, however, 6% of participants developed meningoencephalitis, likely due to anti-Abeta-specific autoimmune Th1 cells. "
11/01/2006 - "The meningoencephalitis observed in the first AD vaccination trial was likely related to excessive cell-mediated immunity caused by the immunogen, amyloid-beta (Abeta) 1-42, and the adjuvant, QS-21. "
02/01/2012 - "Unfortunately, the first active vaccine (AN1792, consisting of preaggregate Aβ and an immune adjuvant, QS-21) was abandoned because it caused meningoencephalitis in approximately 6% of treated patients. "
01/01/2008 - "A recent human clinical trial of an Alzheimer's disease (AD) vaccine using amyloid beta (Abeta) 1-42 plus QS-21 adjuvant produced some positive results, but was halted due to meningoencephalitis in some participants. "
|7.||Acyclovir (Aciclovir)FDA LinkGeneric
01/01/2015 - "She had meningoencephalitis due to HSV at the age of 20 months, and she was treated with acyclovir. "
07/01/2009 - "Three of 4 patients with meningoencephalitis received 21 days of IV acyclovir, and one received 3 days IV acyclovir followed by 14 days of oral therapy. "
11/01/2007 - "Meningoencephalitis was diagnosed and the patient was successfully treated with aciclovir administered at a dose of 30 mg/kg/day for four weeks."
02/01/2002 - "Despite 10 days therapy with intravenous acyclovir, meningoencephalitis developed and the patient died 15 days after onset of neurological symptoms. "
11/01/1999 - "[Cerebral and renal toxicity of acyclovir in a patient treated for meningoencephalitis]."
|8.||Adrenal Cortex Hormones (Corticosteroids)IBA
01/01/1995 - "An aggressive treatment with corticosteroids and immunosuppressive drugs improve the prognosis of meningoencephalitis. "
01/22/1982 - "[Corticoids in the therapy of thick- and other type of viral meningoencephalitis]."
08/09/1974 - "[Corticosteroids in treatment of viral meningoencephalitis (author's transl)]."
02/01/2000 - "These results of these two cases support the efficacy of corticosteroids as adjunctive treatment of diffuse brain edema caused by non-purulent meningoencephalitis. "
07/15/2001 - "Awareness of neurological complication in Sweet's syndrome may avoid unnecessary empiric therapy for meningoencephalitis and will lead to a successful treatment with corticosteroids."
04/01/1995 - "A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin."
01/01/2014 - "Intravenous immunoglobulin induced meningoencephalitis."
01/01/2007 - "Regression of white matter MRI abnormalities in nonvasculitic autoimmune inflammatory meningoencephalitis following intravenous immunoglobulin."
05/09/2005 - "Since active immunization is associated with an autoimmune meningoencephalitis in a subset of humans, passive transfer of anti-Abeta immunoglobulin is being pursued as a potentially safer alternative. "
11/16/2002 - "[Intrathecal synthesis pattern of immunoglobulins in meningoencephalitis epidemic due to echovirus 9]."
|10.||Gentamicins (Gentamicin)FDA LinkGeneric
11/01/2014 - "Furthermore, the administration of ampicillin and gentamicin combination for treatment should be considered as the best therapeutic option in Listeria monocytogenes meningoencephalitis."
04/01/1984 - "The endolymphatic administration of gentamicin in a dose of 80 mg twice a day or ceporin in a dose of 1 g twice a day allowed one to maintain the antibiotic therapeutic levels in the cerebrospinal fluid and to obtain satisfactory clinical results in the combined treatment of meningoencephalitis. "
04/01/1984 - "The efficacy of endolymphatic route of gentamicin and ceporin administration was studied in 89 patients with neurosurgical pathological processes complicated by acute pneumonia (80 patients) and meningoencephalitis (9 patients) usually after ineffective antibiotic therapy according to the routine methods. "
07/01/1989 - "High efficacy of pefloxacin was shown and its advantages over dioxidine and gentamicin on the model of meningoencephalitis were revealed. "
07/01/1999 - "The antibacterial activities of amoxicillin-gentamicin, trovafloxacin, trimethoprim-sulfamethoxazole (TMP-SMX) and the combination of trovafloxacin with TMP-SMX were compared in a model of meningoencephalitis due to Listeria monocytogenes in infant rats. "
02/21/2007 - "The study of CAA is of particular importance for immunotherapeutic approaches to AD, because reports of anti-Abeta immunotherapy in mice and humans have suggested that, whereas CAA appeared resistant to clearance, its response to this treatment promoted potential adverse effects, including meningoencephalitis. "
05/10/2005 - "Reported are MRI findings of a Phase IIa immunotherapy trial in AD prematurely terminated owing to meningoencephalitis in a subset of patients. "
01/01/2005 - "We also discuss the recent Abeta immunotherapy approach vis-à-vis the activated, autoaggressive T-cell infiltrates that contributed to aseptic meningoencephalitis in a small percentage of patients, and present possible alternative approaches that may be both efficacious and safe. "
11/01/2009 - "Immunotherapy holds great promise for Alzheimer's disease (AD), but meningoencephalitis observed in the first AD vaccination trial, which accompanied T-lymphocytic infiltration, needs to be overcome. "
05/10/2005 - "The authors report the results of a phase IIa immunotherapy trial of AN1792(QS-21) in patients with mild to moderate Alzheimer disease (AD) that was interrupted because of meningoencephalitis in 6% of immunized patients. "
09/01/2010 - "We previously reported that intranasal administration of Cry1Ac protoxin alone or in combination with amoebic lysates increases protection against Naegleria fowleri meningoencephalitis in mice. "
01/01/2008 - "According to previous reports, intranasal administration of the Cry1Ac protein alone or with amoebic lysates increases protection against Naegleria fowleri meningoencephalitis in mice, apparently by eliciting IgA responses in the nasal mucosa. "
02/01/1987 - "[Treatment of patients with meningitis and meningoencephalitis caused by acute respiratory virus infection with intranasal administration of a dimexide-nuclease mixture]."
08/01/2010 - "Meningoencephalitis caused by a zygomycete fungus (Basidiobolus) associated with septic shock in an immunocompetent patient: 1-year follow-up after treatment."
10/01/1946 - "Meningoencephalitis complicating herpes zoster ophthalmicus after treatment by vaccination."
03/01/2002 - "Four patients with middle artery infarction showed moderate neurological disorders and one patient with bacterial meningoencephalitis recovered completely after treatment. "
08/01/1991 - "[Electroencephalographic study of meningoencephalitis from Trypanosoma gambiense before and after treatment with melarsoprol]."
01/01/2012 - "Pleconaril revisited: clinical course of chronic enteroviral meningoencephalitis after treatment correlates with in vitro susceptibility."
|4.||Highly Active Antiretroviral Therapy (HAART)
11/01/2011 - "The patient, known HIV positive since 3 years, under HAART (Highly Active Antiretroviral therapy), presented an acute meningoencephalitis which was improved by optimization of treatment for a better CNS (Central Nervous System) penetration according to the CHARTER's (CNS HIV Antiretroviral Therapy Effects Research) score. "
01/01/2015 - "Despite the widespread use of highly active antiretroviral therapy, cryptococcal meningoencephalitis has emerged as the second leading cause of infectious morbidity and mortality in HIV-infected patients worldwide. "
05/01/2009 - "HIV-1 meningoencephalitis in patients on effective HAART."
01/01/2008 - "Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era."
02/01/2007 - "Information on clinical presentation and therapeutic guidelines, derived mostly from clinical trials performed before introduction of highly active antiretroviral therapy in patients with cryptococcal meningoencephalitis, is missing data on extrameningeal involvement and infections by serotype D as opposed to serotype A of Cryptococcus neoformans. "
05/10/2005 - "Following reports of meningoencephalitis (overall 18/300 [6%]), immunization was stopped after one (2 patients), two (274 patients), or three (24 patients) injections. "
11/01/1994 - "In the meningoencephalitis, the levels in cerebrospinal fluid 1 hour after administrations were 1.1 micrograms/ml and 1.5 micrograms/ml in the second and the sixth days respectively, after the start of 4 times a day intravenous bolus injections with 50 mg/kg at each dose; the ratio of the levels in cerebrospinal fluid to those in sera were 0.93% and 2.41% respectively, at the second and the sixth day. "
01/15/2014 - "Injectable immunization using amyloid β peptide (Aβ) comprising 1-42 amino-acid residues (Aβ1-42) as antigens showed therapeutic efficacy in mice; however, the clinical trial of this injected Aβ1-42 vaccine was stopped due to the incidence of meningoencephalitis caused by excess activation of Th1 cells infiltrating the brain as a serious adverse reaction. "